- Home
- GOSS vs ZIMV Comparison
GOSS vs ZIMV Comparison
Compare GOSS & ZIMV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- ZIMV
- Stock Information
- Founded
- GOSS 2015
- ZIMV 2021
- Country
- GOSS United States
- ZIMV United States
- Employees
- GOSS N/A
- ZIMV N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- ZIMV Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- GOSS Health Care
- ZIMV Health Care
- Exchange
- GOSS Nasdaq
- ZIMV Nasdaq
- Market Cap
- GOSS 586.6M
- ZIMV 532.3M
- IPO Year
- GOSS 2019
- ZIMV N/A
- Fundamental
- Price
- GOSS $3.08
- ZIMV $18.90
- Analyst Decision
- GOSS Strong Buy
- ZIMV Hold
- Analyst Count
- GOSS 6
- ZIMV 3
- Target Price
- GOSS $8.60
- ZIMV $14.50
- AVG Volume (30 Days)
- GOSS 4.8M
- ZIMV 653.7K
- Earning Date
- GOSS 11-06-2025
- ZIMV 10-29-2025
- Dividend Yield
- GOSS N/A
- ZIMV N/A
- EPS Growth
- GOSS N/A
- ZIMV N/A
- EPS
- GOSS N/A
- ZIMV N/A
- Revenue
- GOSS $40,237,000.00
- ZIMV $443,402,000.00
- Revenue This Year
- GOSS N/A
- ZIMV $2.49
- Revenue Next Year
- GOSS $34.10
- ZIMV $1.26
- P/E Ratio
- GOSS N/A
- ZIMV N/A
- Revenue Growth
- GOSS N/A
- ZIMV N/A
- 52 Week Low
- GOSS $0.66
- ZIMV $8.15
- 52 Week High
- GOSS $3.60
- ZIMV $19.01
- Technical
- Relative Strength Index (RSI)
- GOSS 61.72
- ZIMV 75.07
- Support Level
- GOSS $2.93
- ZIMV $18.85
- Resistance Level
- GOSS $3.37
- ZIMV $18.93
- Average True Range (ATR)
- GOSS 0.29
- ZIMV 0.05
- MACD
- GOSS 0.01
- ZIMV -0.15
- Stochastic Oscillator
- GOSS 57.55
- ZIMV 35.29
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About ZIMV ZimVie Inc.
ZimVie Inc is focused on the dental and spine markets and their respective growth drivers such as implants, surgical tools, bone graft substitutes, spinal fusion implants, non-fusion alternatives, and digital care management solutions. Business is organized into two operating segments the spine products segment and the dental products segment.